MEIRAGTX HOLDINGS

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

GAAP

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Company estimates that its cash and cash equivalents on hand, accounts receivable - related party and tax incentive receivable at December 31, 2024 will be sufficient to cover its expenses for at least the next twelve months from the date of issuance of these consolidated financial statements.”

Group structure

1. MEIRAGTX HOLDINGS · parent
   1. MeiraGTx Limited · England and Wales
   2. MeiraGTx, LLC · Delaware
   3. MeiraGTx UK II Limited · England and Wales
   4. MeiraGTx Ireland DAC · Ireland
   5. MeiraGTx Netherlands B.V. · Netherlands
   6. MeiraGTx Belgium · Belgium
   7. BRI-Alzan, Inc. · Delaware
   8. MeiraGTx Bio Inc. · Delaware
   9. MeiraGTx B.V. · Netherlands
   10. MeiraGTx Neurosciences, Inc. · Delaware
   11. MeiraGTx Therapeutics, Inc. · Delaware
   12. MeiraGTx UK Limited · England and Wales
   13. MeiraGTx Neuro I, LLC · Delaware
   14. MeiraGTx Neuro II, LLC · Delaware
   15. MeiraGTx Manufacturing Limited · England and Wales
   16. MeiraGTx Ocular UK Limited · England and Wales
   17. MeiraGTx Gene Regulation Limited · England and Wales
   18. MeiraGTx Neuro UK Limited · England and Wales

Significant events

• “On January 30, 2019, the Company entered into a collaboration, option and license agreement with Janssen Pharmaceuticals, Inc.”
• “On December 20, 2023, the Company entered into an Asset Purchase Agreement with Janssen pursuant to which the Company sold and assigned to Janssen, and Janssen purchased and assumed, that certain License Agreement.”
• “In December 2023, the Company entered into an "at-the-market" sales agreement with BofA Securities, Inc., or BofA, pursuant to which the Company may sell from time to time, ordinary shares having an aggregate offering price of up to $100.0 million.”
• “On August 12, 2024, the Company entered into an underwriting agreement with BofA in connection with the issuance and sale by the Company in a public offering of 12,500,000 of the Company's ordinary shares.”
• “On August 12, 2024, the Company agreed to sell shares to an accredited investor (the "Investor") through a private placement for gross proceeds of $1.0 million.”
• “On May 3, 2023, the Company entered into a securities purchase agreement with certain accredited investors, pursuant to which the Company, in a private placement, agreed to issue and sell an aggregate of 10,773,913 ordinary shares.”
• “On October 30, 2023, the Company entered into an Investment Agreement with Sanofi Foreign Participations B.V., a wholly-owned subsidiary of Sanofi, and solely for the limited purposes set forth therein, Sanofi, pursuant to which, the Company, in a private placement, issued an aggregate of 4,000,000 ordinary shares.”
• “On March 9, 2025 (the "Signing Date"), the Company and its affiliates entered into a strategic collaboration with Hologen Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

1

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +137.4%

  £10,390,660 → £24,669,385

• Cash

  -20%

  £96,045,960 → £76,841,364

• Net assets

  -50.9%

  £102,429,207 → £50,279,466

• Employees

  —

  Not reported

• Operating profit

  -19.8%

  -£101,601,927 → -£121,728,688

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers